Therapeutic Value of Silymarin as Iron Chelator in Children with Beta Thalassemia with Iron Overload
Adel A Hagag* and Mokhtar Abd Elfatah
Department of Pediatrics, Faculty of Medicine, Tanta University, Egypt
- *Corresponding Author:
- Adel A Hagag
Department of Pediatrics, Faculty of Medicine
Tanta University, Egypt
E-mail: [email protected]
Received date: January 06, 2014; Accepted date: March 04, 2014; Published date: March 08, 2014
Citation: Hagag AA, Abd Elfatah M (2014) Therapeutic Value of Silymarin as Iron Chelator in Children with Beta Thalassemia with Iron Overload. J Leuk (Los Angel) 2:132. doi: 10.4172/2329-6917.1000132
Copyright: © 2014 Hagag AA, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Beta thalassemia is an inherited hemoglobin disorder resulting in chronic hemolytic anemia. The most common treatment for thalassemia is blood transfusion which is necessary to provide the patients with healthy red blood cells containing normal hemoglobin. Repeated blood transfusion leads to iron overload. Excess iron is deposited in body organs as liver, heart and endocrine glands causing organ damage. Iron chelation therapy is the main way to treat iron overload in beta thalassemia major. Silymarin and its biologically active component Silybin are strong antioxidant and have documented iron chelating activities in patients with beta-thalassemia major. The aim of this review was to spotlight on the therapeutic value of silymarin as iron chelator in children with beta thalassemia major with iron overload.